Antimelanoma effect of a fucoxylomannan isolated from Ganoderma lucidum fruiting bodies

A fucoxylomannan (FXM) was isolated from the mushroom Ganoderma lucidum through alkaline extraction followed by dialysis, freeze-thawing, and fractionation by Fehling's solution. The main chain of FXM presented alpha-D-Manp-(1 -> 4)-linked units, and some of them were branched at O-6 position by alpha-L-Fucp-(1 -> 2)-beta-D-Xylp groups. Its Mw was 35.9 kDa. FXM was tested on melanoma B16-F10 cells and it showed cell viability and cell density reduction, as well as antiproliferative effect, through cell cycle arrest. Additionally, the anchorage -independent clonogenic capacity of such cells was significantly reduced by FXM, decreasing the number of cells by colony and the colonies area. No effect on viability neither in proliferation of non-tumoral Balb c/3T3 fibroblasts was observed. These results indicate that FXM is a promising anti-proliferative compound impairing pivotal tumorigenic mechanisms, eliciting this polysaccharide to be further explored as an antimelanoma drug.

Automated summary

In this study, a fucoxylomannan (FXM) was isolated from Ganoderma lucidum mushroom, which exhibited anti-proliferative effects on melanoma cells, including reduction in cell viability, cell density, and anchorage-independent clonogenic capacity. However, no impact on non-tumoral cells was observed.